Navigation Links
Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
Date:11/2/2011

NATICK, Mass., Nov. 2, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has completed a $10M Series A2 financing which complements the $20M Series A financing announced one year ago. Both Series A and A2 were lead by Chione Ltd. This brings the total raised by the Company to approximately $32M since its inception. The funds will be used to expand the planned Phase I program, targeted to begin in mid 2012 with Karyopharm's oral selective inhibitors of nuclear export (SINE) for various cancers.  The Company is also evaluating related transport modulators for use in dermatologic, inflammatory, and viral disorders.

Michael Kauffman, MD, PhD, Karyopharm's CEO, remarked, "This funding shows the confidence our investors have in our progress and platform. With these additional resources, we are able to move our oral clinical SINE compound for oncology into Phase I studies in both hematologic and solid tumor malignancies. The oral bioavailability and preliminary tolerability of the compounds allow us to investigate these agents for indications outside of cancer, including autoimmune, inflammatory and viral disorders.  We look forward to bringing the first SINE therapeutic to patients with cancer in the coming year."

Karyopharm is the leader in the development of nuclear transport modulators for the treatment of cancer, autoimmune, dermatologic, and viral diseases. These SINEs act by forcing the nuclear localization of major tumor suppressor and growth regulatory proteins, causing selective death of cancer cells while sparing normal cells. The Karyopharm platform, utilizing rapid chemical optimization with integrated computational/in silico rational drug design, has yielded multiple novel active small molecule SINEs, which have shown activity in a variety of animal models.

About Karyopharm

Karyopharm is a biopharmaceutical company leading the development of smal
'/>"/>

SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
2. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
3. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
6. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
7. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
8. Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
9. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
10. Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
11. Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... and sales and operations planning ( S&OP ) service, is ... Summit , which will be held at the Hilton San ... join Kinaxis customer Elisabeth Kaszas , Director of Supply ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
(Date:1/14/2014)... 14, 2014 Holloway America today announced ... material test reports (MTRs) for all pressure vessels and ... results is particularly important for equipment that must meet ... Library features search functionality that allows authorized users to ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... 6, 2011 Spinal muscular atrophy (SMA) is the leading ... treatment other than supportive care. In the Proceedings of ... June 6), researchers at Children,s Hospital Boston show how loss ... and weakness, and suggest a promising approach to treating the ...
... 6, 2011 Oxford BioMedicaplc ("Oxford BioMedica" ... company, today announces that it has signed a research ... specialising in the development of engineered antibody fragments for ... in vivo diagnostic imaging agent using an ...
... Ganeden Biotech announced the sale of ... brands of probiotic dietary supplements to Schiff ...  Ganeden will also receive royalties on Schiff products containing ... rights to use Ganeden,s probiotic technology, GanedenBC30™, in the ...
Cached Biology Technology:New Approaches Open up in Spinal Muscular Atrophy 2New Approaches Open up in Spinal Muscular Atrophy 3Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb 2Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb 3Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 2Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 3
(Date:4/23/2014)... of Exeter researcher has shed light on how an ... Australia,s remote outback have become reviled as pests and ... the Environment and Sustainability Institute at the University of ... in Australia, from their historic role helping to create ... unwelcome "invader." , The deserts of the Australian outback ...
(Date:4/23/2014)... social mammals, ravens form different types of social relationships ... they also form strict dominance relations. From a cognitive ... key ability in daily social life ("knowing who is ... members have with each other sets the stage for ... of this study have been published in the scientific ...
(Date:4/23/2014)... a 2 million Food Standards Agency (FSA) project to ... industry workers. , Norovirus outbreaks can rapidly affect ... of frozen strawberries infected 11,000 people in Germany, but ... which strains cause infection and which foods are the ... Researchers will produce data that will help the FSA ...
Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Ravens understand the relations among others 2
... available in German . , A new ... could help to understand the positive effect of dietary restriction ... and mice) have shown that dietary restriction increases longevity, but ... the female fruit fly reproduces less frequently with a reduced ...
... discovery is challenging accepted thinking about amyloids the fibrous ... and may open up a potential new area for ... structures made up of proteins sometimes known as fibres - ... their formation which can damage cells and cause disease. ...
... Hausen and his co-workers discovered that specific types of human ... these pathogens cause cells to degenerate. It is known today ... Both proteins switch off different cellular control functions, thus promoting ... co-workers at DKFZ have now discovered another mechanism by which ...
Cached Biology News:How nutrition affects healthy aging 2New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2
... the Quansys Biosciences Q-Plex Array is a ... for human, mouse, and rat research. The ... quantitative ELISA-based test where 4 distinct capture ... of a 96-well plate in a defined ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... kit for 10 chips provides the chips ... with the Experion automated electrophoresis system. This ... x 520 microliters Pro260 gel, 45 microliters ... kD), 400 microliters Pro260 sample buffer, and ...
... The expertise that made the original Gene ... electroporation system available has been applied in the ... circuitry. The modular design of the Gene Pulser ... the accessory that has the widest range of ...
Biology Products: